Latest Market News

Linius Technologies has released its audited FY2025 financial statements, revealing non-cash accounting adjustments related to Convertible Notes that increased reported losses and liabilities compared to prior unaudited figures.

EMVision Medical Devices has launched a Share Purchase Plan allowing shareholders to invest up to A$30,000 at $1.94 per share, sweetened by free-attaching options exercisable at $3.40 each.

OzAurum Resources has launched a targeted drilling campaign at its Mulgabbie North Gold Project, aiming to expand high-grade zones and advance feasibility studies amid record gold prices.

Dalrymple Bay Infrastructure has appointed CEO Michael Riches as Managing Director, coinciding with the resignation of two non-executive directors following a significant shareholder sell-down.

Altech Batteries has partnered with AMPower to immediately market and distribute sodium nickel chloride batteries across Europe, Australia, and the USA, fast-tracking revenue ahead of its large-scale CERENERGY project in Germany.

EMU NL’s securities have been suspended from ASX trading due to a failure to maintain the minimum number of directors required by law. The suspension highlights governance challenges and raises questions about the company’s path to compliance.

Peak Rare Earths has officially been acquired by Shenghe Resources, with shareholders paid $0.443 per share and delisting from the ASX imminent. This marks a significant consolidation in the rare earths sector.

The Star Entertainment Group has finalized a crucial covenant waiver with its syndicated lenders, easing financial pressures ahead of its FY2025 audited report. This development clarifies ongoing negotiations and sets the stage for the company’s next financial chapter.

Lakes Blue Energy has wrapped up drilling at its Wombat-5 well in Victoria’s Gippsland Basin, setting the stage for critical gas flow testing to assess commercial potential.

Uscom Limited has struck a deal to sell its entire business to Singapore-based AXO Medtech VCC for $2.59 million, aiming to unlock capital for growth under new ownership. Shareholder approval is the next critical step before the transaction can proceed.

Invex Therapeutics Ltd has had its trading suspension lifted following the announcement of a material acquisition, signaling a pivotal moment for the biotech company.

Invex Therapeutics reveals the collapse of confidential acquisition negotiations following shareholder unrest and potential board changes, clarifying recent unusual trading activity.